Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

Abstract This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare disease, myasthenia gravis. Terminal Compl...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Tuan Vu, Andreas Meisel, Renato Mantegazza, Djillali Annane, Masahisa Katsuno, Rasha Aguzzi, Ahmed Enayetallah, Kathleen N. Beasley, Nishi Rampal, James F. Howard
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Adis, Springer Healthcare 2023-06-01
Saila:	Neurology and Therapy
Gaiak:	Anti-AChR antibody Complement Monoclonal antibody Myasthenia gravis Ravulizumab Patient-centered outcomes
Sarrera elektronikoa:	https://doi.org/10.1007/s40120-023-00514-4
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!